Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research 2014, 20: 6406-6417. PMID: 25326230, PMCID: PMC4300523, DOI: 10.1158/1078-0432.ccr-14-1271.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSuit-2 cell lineOrthotopic xenograft mouse modelBioluminescence imagingFavorable toxicity profileSublethal drug concentrationsAnti-invasive effectsXenograft mouse modelPDAC cell linesCell linesXenograft tumor modelHalf maximal inhibitory concentrationStrong anticancer effectsPancreatic cancerClinical trialsDuctal adenocarcinomaMouse modelToxicity profileIC50 profileTherapeutic efficacyMatrigel invasionVivo efficacyBLI signalMatrigel assaysMiaPaCa-2Reversal of Anchorage-Independent Multicellular Spheroid into a Monolayer Mimics a Metastatic Model
Kunjithapatham R, Karthikeyan S, Geschwind JF, Kieserman E, Lin M, Fu DX, Ganapathy-Kanniappan S. Reversal of Anchorage-Independent Multicellular Spheroid into a Monolayer Mimics a Metastatic Model. Scientific Reports 2014, 4: 6816. PMID: 25351825, PMCID: PMC4212233, DOI: 10.1038/srep06816.Peer-Reviewed Original ResearchConceptsMetastatic phenotypeAnchorage-independent growthMolecular regulationMulticellular spheroidsStem cell markersMolecular eventsCancer stem cell markersVitro modelModel of metastasisMetastatic processSpecific therapeutic targetsTherapeutic targetAntimetastatic agentPhenotypeMetastatic modelRegulationVivo dataExpressionChemoresistanceInvasivenessSpheroidsMajor impedimentInductionMimicsGrowth